Cite
HARVARD Citation
Gautam, A. et al. (2018). Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat. Leukemia & lymphoma. 59 (1), pp. 69-76. [Online].